Ibrutinib (Imbruvica) for Lymphoma


( Last Updated : July 17, 2019)
Generic Name:
Ibrutinib
Project Status:
Not filed
Manufacturer:
Janssen Canada Inc.
Brand Name:
Imbruvica
Project Line:
Reimbursement Review
Project Number:
N/A

Details


Tumour Type:
Lymphoma
Indications:
In combination with rituximab for Waldenstrom's Macroglobulinemia
Review Status:
Not Filed
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Clarification:
CADTH is unable to recommend reimbursement of the relevant product because a submission to CADTH was not filed by the manufacturer.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.